47 ± 19 ml/min/1.73 m2), their changes in allograft eGFR were similar (+1.0 ± 4.9 vs. −0.2 ± 6.9 ml/min/1.73 m2/year, p = 0.50).

None of the patients in the FX group experienced any severe adverse effects, such as pancytopenia or attacks of gout, throughout the entire study period. Nephrologists were more likely than urologists to start febuxostat in recipients with PTHU (69% vs. 8%). Conclusion: Treatment with febuxostat sufficiently lowered UA without severe adverse effects in stable kidney transplant PCI-32765 in vivo recipients with PTHU. LAM CHUNG MAN, CHEUK AU, TANG HON LOK, FUNG KA SHUN, SAMUEL Renal Unit, Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong Introduction: Proliferation Signal Inhibitor (PSI) is a novel class of immunosuppressant which inhibits mammalian target of rapamycin (mTORi). It has been suggested as an alternative

immunosuppressive agent to calcineurin inhibitors (CNI) or mycophenolate mofetil (MMF)/ Mycophenolic acid (MPA) in renal-transplant recipients. It Fostamatinib clinical trial has potential role in alleviating calcineurin inhibitors (CNI) induced nephrotoxicity and chronic allograft nephropathy (CAN). Studies on the clinical application of PSI in local population are sparse. Methods: We performed a retrospective study to evaluate the 12 months efficacy and safety after conversion to PSI in renal transplant recipients in Princess Margaret Hospital since 2003. Totally 62 patients were recruited. Results: Renal function determined by estimated glomerular filtration rate at one year was significantly better in the PSI group (52.01 ± 18.15 ml/min at baseline vs 56.46 ± 19.98 at one year (P < 0.003)).

Most improvement was seen in patient with early primary conversion and higher GFR group (GFR > 40 ml/min). The incidence of biopsy-proven acute rejection after conversion was not different from the other trials. Increase in proteinuria and lipid were more significant after PSI conversion. Conclusion: Conversion to PSI may be a useful strategy to improve renal function. The adverse effects are usually well tolerated. Early conversion may be more beneficial than late conversion. Appropriate selection of candidates for PSI conversion, and early identification Sinomenine and prompt management of PSI induced adverse events, reduce serious complication and improve outcome. Subgroup analysis Lipid and proteinuria Demographics UYAR MEHTAP ERKMEN1,2,3,4, SEZER SIREN1, DEMIRCI BAHAR GURLEK1, BAL ZEYNEP1, TUTAL EMRE1, HASDEMIR EFE2, COLAK TURAN1, OZDEMIR ACAR FATMA NURHAN3, HABERAL MEHMET4 1Baskent University, Department of Nephrology, Ankara, Turkey; 2Baskent University, Department of Internal Medicine, Ankara, Turkey; 3Baskent University, Department of Nephrology, Istanbul, Turkey; 4Baskent University, Department of Transplantation Surgery, Ankara, Turkey Introduction: New-onset diabetes after solid organ transplantation is an important clinical challenge associated to increased risk of cardiovascular (CV) events.